Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics
DAWN Price/Volume Stats
| Current price | $7.19 | 52-week high | $16.76 |
| Prev. close | $6.95 | 52-week low | $6.08 |
| Day low | $7.02 | Volume | 1,445,700 |
| Day high | $7.33 | Avg. volume | 1,253,429 |
| 50-day MA | $7.04 | Dividend yield | N/A |
| 200-day MA | $11.36 | Market Cap | 728.79M |
DAWN Stock Price Chart Interactive Chart >
Day One Biopharmaceuticals, Inc. (DAWN) Company Bio
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DAWN Price Returns
| 1-mo | 6.36% |
| 3-mo | -17.07% |
| 6-mo | -46.62% |
| 1-year | -43.70% |
| 3-year | 1.99% |
| 5-year | N/A |
| YTD | -43.25% |
| 2024 | -13.22% |
| 2023 | -32.16% |
| 2022 | 27.72% |
| 2021 | N/A |
| 2020 | N/A |